Jianqing Lin

Hematology | Oncology | Internal Medicine

2010 Health Campus Dr
Harrisonburg, VA 22801

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Tumor microenvironment-responsive cerium oxide nanozyme coated ZIF-8 nanoplatform with ICG encapsulation for precise breast cancer surgery and efficacious synergistic suppression.

Tumor microenvironment-responsive cerium oxide nanozyme coated ZIF-8 nanoplatform with ICG encapsulation for precise breast cancer surgery and efficacious synergistic suppression.

Journal: Materials today. Bio

Published: September 04, 2025

UBE2R2-AS1, as a prognostic marker of gastric cancer, promotes the malignant phenotype of gastric cancer cells.

UBE2R2-AS1, as a prognostic marker of gastric cancer, promotes the malignant phenotype of gastric cancer cells.

Journal: Histology and histopathology

Published: November 27, 2023

Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.

Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.

Journal: Prostate cancer and prostatic diseases

Published: May 15, 2023

Management of Localized Prostate Cancer in Men With Human Immunodeficiency Virus: Analysis of a Large Retrospective Cohort.

Management of Localized Prostate Cancer in Men With Human Immunodeficiency Virus: Analysis of a Large Retrospective Cohort.

Journal: Clinical genitourinary cancer

Published: January 12, 2023

Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.

Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.

Journal: Current oncology reports

Published: October 12, 2022

ONECUT2 as a key mediator of androgen receptor-independent cell growth and neuroendocrine differentiation in castration-resistant prostate cancer.

ONECUT2 as a key mediator of androgen receptor-independent cell growth and neuroendocrine differentiation in castration-resistant prostate cancer.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: October 01, 2021

Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.

Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.

Journal: The oncologist

Published: April 14, 2021

Cardiovascular Toxicity of Androgen Deprivation Therapy.

Cardiovascular Toxicity of Androgen Deprivation Therapy.

Journal: Current cardiology reports

Published: March 04, 2021

Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma.

Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma.

Journal: Journal of kidney cancer and VHL

Published: January 27, 2021

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.

Journal: BMC cancer

Published: December 31, 2020

Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment.

Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment.

Journal: Asian journal of andrology

Published: November 27, 2020

Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer.

Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer.

Journal: Cancers

Published: November 12, 2020

Showing 1-12 of 38

Last Updated: 09/26/2026